Innovative drug Xinrui Hui Pharmaceuticals announced the completion of the B-plus round of financing

It was learned that recently, innovative pharmaceutical company Bionova Pharmaceuticals (Yuhui Pharmaceuticals) announced the completion of the B-plus round of financing.
this round by Hanxuan Capital, Jinpu Investment, Power Capital, Yanlian Health Fund, Yin Shengtai and other joint investment.
the company has completed two rounds of financing, including Taifu Capital, Gaoli Capital, Obo Capital, Boyuan Capital, Lilly Asia Fund, Power Capital and Mitsui International Investment.
Pharmaceuticals was established in 2018 to focus on the field of oncology.
Relying on the founding team's deep understanding of china's pharmaceutical market, rich clinical research, as well as many years of experience in new drug development and trading, with the "product introduction and independent research and development" combined model, for clinical treatment there are still diseases that do not meet medical needs, is committed to the development of innovative drugs to fill the treatment gap.
note: There are deletions in the original text